Traditional Cryoprecipitate + Pathogen-Reduced Cryoprecipitate
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hypofibrinogenemia
Conditions
Hypofibrinogenemia, Bleeding
Trial Timeline
Apr 1, 2023 → Oct 3, 2025
NCT ID
NCT05711524About Traditional Cryoprecipitate + Pathogen-Reduced Cryoprecipitate
Traditional Cryoprecipitate + Pathogen-Reduced Cryoprecipitate is a approved stage product being developed by Cerus for Hypofibrinogenemia. The current trial status is completed. This product is registered under clinical trial identifier NCT05711524. Target conditions include Hypofibrinogenemia, Bleeding.
Hype Score Breakdown
Clinical
20
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05711524 | Approved | Completed |
Competing Products
1 competing product in Hypofibrinogenemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pathogen Reduced Cryoprecipitated Fibrinogen Complex + Cryoprecipitated-Antihemophilic Factor | Cerus | Pre-clinical | 23 |